
Bertrand Dunogué

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8363881/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Revisiting characteristics, treatment and outcome of cardiomyopathy in eosinophilic granulomatosis with polyangiitis (formerly Churg–Strauss). Rheumatology, 2022, 61, 1175-1184.	0.9	11
2	Characteristics of thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly syndrome: a retrospective study from a large Western cohort. British Journal of Haematology, 2022, 196, 599-605.	1.2	5
3	Elastic Registration–driven Deep Learning for Longitudinal Assessment of Systemic Sclerosis Interstitial Lung Disease at CT. Radiology, 2021, 298, 189-198.	3.6	28
4	Impact of Cardiovascular Risk Factors on the Occurrence of Cardiovascular Events in Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitides. Journal of Clinical Medicine, 2021, 10, 2299.	1.0	9
5	Rapid identification and characterization of infected cells in blood during chronic active Epstein-Barr virus infection. Journal of Experimental Medicine, 2020, 217, .	4.2	37
6	Non-Aspergillus Fungal Infections in Chronic Granulomatous Disease. Current Fungal Infection Reports, 2019, 13, 59-66.	0.9	3
7	Abdominal adipose tissue predicts major cardiovascular events in systemic necrotising vasculitides. Clinical and Experimental Rheumatology, 2019, 37 Suppl 117, 130-136.	0.4	2
8	Relevance of diagnostic investigations in patients with uveitis: Retrospective cohort study on 300 patients. Autoimmunity Reviews, 2017, 16, 504-511.	2.5	46
9	Revisiting the systemic vasculitis in eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Autoimmunity Reviews, 2017, 16, 1-9.	2.5	140
10	Employment, work disability and quality of life in patients with ANCA-associated vasculitides. The EXPOVAS study. Clinical and Experimental Rheumatology, 2017, 35 Suppl 103, 40-46.	0.4	9
11	Granulomatosis with polyangiitis according to geographic origin and ethnicity: clinical-biological presentation and outcome in a French population. Rheumatology, 2016, 56, kew423.	0.9	3
12	Pharmacological approach to treating eosinophilic granulomatosis with polyangiitis (Churg–Strauss). Expert Opinion on Orphan Drugs, 2015, 3, 505-515.	0.5	0
13	Eosinophilic granulomatosis with polyangiitis (Churg–Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. European Journal of Internal Medicine, 2015, 26, 545-553.	1.0	371
14	Impact of cardiac magnetic resonance imaging on eosinophilic granulomatosis with polyangiitis outcomes: A long-term retrospective study on 42 patients. Autoimmunity Reviews, 2015, 14, 774-780.	2.5	37
15	Diagnosis and classification of eosinophilic granulomatosis with polyangiitis (formerly named) Tj ETQq1 1 0.7843	14 rgBT /0	Overlock 10

¹⁶Churg-Strauss Syndrome: Clinical Symptoms, Complementary Investigations, Prognosis and Outcome, 0.8 41 and Treatment. Seminars in Respiratory and Critical Care Medicine, 2011, 32, 298-309.